课题基金 / 基金详情

项目摘要

项目成果

Audra L. Stinchcomb的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):目前丁丙诺啡(BUP)用于治疗阿片类药物滥用和疼痛管理。它也可以作为阿片类药物不当使用和滥用。在美国,丁丙诺啡以舌下和注射形式销售。虽然药物提供了有效的治疗,但这些形式的药物传递是不可取的,因为它们的峰值血浆水平相关的副作用和作用时间短。经皮给药减少了与峰值相关的副作用,并且是慢性治疗的理想选择,因为一个贴片可以在长达一周的时间内以恒定的速率给药。初步积极的初步数据鼓励AllTranz寻求资金来开发新的丁丙诺啡前药,并通过透皮贴片或凝胶给药系统优化其使用。前药是经过化学修饰的母体药物,比母体药物更具有皮肤渗透性,一旦穿过角质层,它们就会迅速分离回母体药物和前药部分。我们还将为这种阿片类药物输送系统制定防止滥用的配方。透皮给药系统,贴片和凝胶,提供了许多其他给药系统的改进。贴片和凝胶不需要吞咽,消除了口服副作用和阿片类药物苦味的担忧;它们也不需要用针头刺穿皮肤,从而消除了疼痛和病人看医生的时间。通过皮肤渗透使药物直接进入体循环,避免了首过效应,减少了肝损害药物滥用者和危重患者的胃副作用和肝损害作用。在欧洲可用的透皮BUP系统可以受益于更高的皮肤渗透率,改善粘附性,滥用威慑机制,更小的贴片尺寸,使用后残留在贴片中的残留药物更少,以及透皮凝胶的最终剂量灵活性。制剂中所需药物的减少意味着移除贴片后潜在滥用药物的减少,因为目前欧洲销售的贴片在治疗结束时仍含有其药物负荷的50%。为了使滥用更加困难,我们将开发一种含有阿片类拮抗剂非渗透性前药和/或包被颗粒的滥用威慑制剂。改变后的拮抗剂将保留在贴片或凝胶中,不会以治疗速率进入体内,但如果试图通过注射或口腔途径滥用BUP,则会阻断BUP的欣快效果。具体来说,我们的目标是合成BUP的前药,并与纳曲酮一起制造一种滥用威慑成分。然后,我们的目标是评估他们的体外人体皮肤渗透的最佳通量。将对最佳药物进行联合和重新评估,以确定该制剂在透皮转运过程中增加了前药BUP的渗透,同时阻止了改变后的纳曲酮的递送。在进一步的研究中,我们将开发原型产品,申请IND并开始I期临床试验。我们将开发一种可销售的透皮药物,这将大大有助于治疗海洛因滥用和慢性疼痛。
英文摘要
DESCRIPTION (provided by applicant): Currently buprenorphine (BUP) is used in the treatment of opioid abuse and for pain management. It can also be used improperly and abused as an opioid. In the United States, buprenorphine is marketed in sublingual and injectable forms. While the drug provides effective treatment, these forms of drug delivery are not desirable because of their peak plasma level related side effects and short duration of action. Transdermal delivery of drugs decreases peak-related side effects, and is ideal for chronic therapies as one patch can deliver a constant rate of drug for up to one week. Initial positive preliminary data has encouraged AllTranz to seek funding to develop new buprenorphine prodrugs and optimize their use through a transdermal patch or gel drug delivery system. Prodrugs are chemically modified parent drugs that are more skin permeable than the parent, and once they cross the stratum corneum quickly separate back into the parent drug and prodrug moiety. We will also create formulations for abuse deterrence for this opioid delivery system. Transdermal delivery systems, patches and gels, offer a number of improvements over other delivery systems. Patches and gels do not require swallowing, eliminating oral side effects and bitter opioid taste concerns; nor do they require skin puncture by needles, eliminating pain and patient visits to a physician. Permeation through the skin allows the drug to directly enter the systemic circulation and avoid the first pass effect, decreasing gastric side effects and liver damage effects in hepatocompromised drug abusers and critically ill patients. The transdermal BUP system that is available in Europe could benefit from a higher skin permeation rate, improvement in adhesion, an abuse deterrent mechanism, a smaller patch size, less residual drug remaining in the patch after use, and the ultimate dosing flexibility of a transdermal gel. Less drug needed in the formulation means less drug for potential abuse when the patch is removed, as currently the European marketed patches still contain fifty percent of their drug load at the end of treatment. To make abuse more difficult still, we will create an abuse deterrent formulation with opioid antagonist non-permeating prodrug and/or coated particles. The altered antagonist will remain in the patch or gel and not enter the body at a therapeutic rate, but will block the euphoria effect of BUP if abuse is attempted via the injectable or buccal routes. Specifically we aim to synthesize prodrugs of BUP and create an abuse deterrent component with naltrexone. We then aim to assess their in vitro human skin permeation for optimum flux. The optimal drugs will be combined and reassessed to see that the formulation provides increased permeation of BUP from prodrug during transdermal transport while the delivery of altered naltrexone is prevented. In further studies we will develop the prototype product and apply for an IND and begin Phase I clinical trials. We will create a marketable transdermal drug that will significantly ai in the treatment of heroin abuse and chronic pain. Public Health Relevance: AllTranz is seeking funding to create a transdermal prodrug gel and improved patch of buprenorphine for treatment of opioid dependence and chronic pain. These transdermal systems would be abuse deterrent and more effective than currently marketed products of the controlled substance buprenorphine. The gel would be a non-invasive non-oral dosage form with ultimate dosing flexibility without the need for patch cutting. The patches will be designed to have less residual drug content after use making them more appealing from a regulatory perspective, they could have better adhesion properties if less of a more permeable drug could be used, and when higher delivery rates are desirable in terminal pain the patient would benefit from the increased drug loading possible with the faster prodrug permeation allowing a smaller patch size to be used.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heat Effect on Generic Transdermal Drug Delivery Systems
  • 批准号:
    9340991
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2013
  • 负责人:
    Audra L. Stinchcomb
  • 依托单位:
Transdermal Naltrexone for Opiate Addiction and Alcoholism
  • 批准号:
    8253142
  • 项目类别:
  • 资助金额:
    $53.78万
  • 财政年份:
    2012
  • 负责人:
    Audra L. Stinchcomb
  • 依托单位:
Microneedle-enhanced codrug delivery for smoking cessation and appetite suppressi
  • 批准号:
    8508902
  • 项目类别:
  • 资助金额:
    $23.01万
  • 财政年份:
    2012
  • 负责人:
    Audra L. Stinchcomb
  • 依托单位:
Transdermal Naltrexone for Opiate Addiction and Alcoholism
  • 批准号:
    8519709
  • 项目类别:
  • 资助金额:
    $69.6万
  • 财政年份:
    2012
  • 负责人:
    Audra L. Stinchcomb
  • 依托单位:
海外基金